First Human Receives Experimental Vaccine Against Rare Ebola Strain

Researchers at the University of Oxford have administered the first dose of an experimental vaccine designed to protect against the Bundibugyo strain of Ebola, marking the world’s first human trial for a vaccine targeting this rare but deadly virus. The Phase I clinical trial, named BD-Ebov, will enroll 50 healthy adults aged 18 to 55 to evaluate the vaccine’s safety and its ability to trigger an immune response.